The American Society of Rheumatology lists depresinatrol as a first-line treatment for uric acid.

, June 30, 2020 -- The American Rheumatology Society's Gout Management Guide (2020 Edition) was published online at the same time by Arthritis Rheumatol and Arthritis Care ResThe 2020 edition of the new ACR guidelines introduces 42 recommendations on the control of acute gout, the usual reduction of uric acid and the prevention of seizures, and the use of medication when comorbiditiesOne of the most important updates is to retain only peripurin as a first-line uric acid reduction drug option: all patients with hyperuric acidemia (HUA) are presented, including CKD (Phase 3) moderate and severe patients, and it is highly recommended to prefer pentol as a first-line drug to reduce uric acid.Perpreormisol is a drug that inhibits uric acid synthesis, after entering the human body, peripurinol and its metabolized product oxycodone alcohol can inhibit jaundice oxidase, prevent the metabolism of jaundice and jaundice metabolize into uric acid, thereby reducing the production of uric acid, so that the uric acid content in blood and urine is reduced to below solubility, preventing the formation of uric acid in joints and other tissues, and also helps gout patients re-crystalmelet.Since the listing of peripurinol, the clinical efficacy has been widely recognized by the vast number of doctors and patientsAt home and abroad major authorities and medical guidelines have recommended depresinof alcohol as a treatment of hyperuric acid emisis first-line drugs.In 2011, the Chinese Medical Association and the Chinese Gerontology Society organized experts in the field to re-discuss the relationship between HUA and cardiovascular disease and the need for treatment, and issued the "Recommendations for the diagnosis and treatment of cardiovascular disease with asymptomatic hyperuric acidemia" (second edition)Recommended "Omaibili (beulwantol slow release capsule)" to treat primary and secondary hyperuric acidemia, especially hyperuric acid emis caused by excessive uric acid production; Compared with other uric acid-lowering drugs in the same class, safe and effective side effects are low.The European Union against Rheumatology (EULAR) 2016 proposed jaundice oxidase inhibitors (XOI) as the preferred drug for uric acid reduction therapy, and the British Rheumatology Society (BSR) recommended desalpalone as a first-line uric acid reduction (ULT) drug in 2017The 2019 edition of China's Guidelines for the Diagnosis and Treatment of Hyperuretic Seromia and Gout recommends phenosis as a first-line drug for uric acid reduction in patients with gout and asymptomatic hyperuric acid, and the newly released gout management guidelines of the American Rheumatology Society (ACR) in 2020 retain only penopursis as a first-line anti-uric acid drug.Hyperuric acidemia (HUA) is the most important biochemical pathological basis leading to gout, gout is a common metabolic disorder syndrome caused by excessive uric acid production or poor uric acid excretion, is a recurrent inflammatory disease caused by uric acid crystal depositin in joint slip membranes, sacs, cartilage and other tissues, and clinically also belongs to the category of metabolic rheumatismSevere gout patients can have joint disability and renal insufficiency, which seriously affect seisphons
health
and quality of life.The prevalence of hyperuric acidemia (HUA) and gout in China has increased dramaticallyThe 2019 edition of China's Guidelines for the Diagnosis and Treatment of Hyperuretic Sewhoemiasis and Gout suggests that hyperuric acidemia has shown a marked upward and younger trend in recent yearsThe overall prevalence of hyperuric acidemia in China is 13.3% and gout is 1.1%, which has become a common metabolic disease that must be paid attention to after diabetes, and hyperuric acidemia has been, high blood sugar and hyperlipidemia withhypertension and is called the "new four highs" of human health threatA large number of evidence-based medical evidence at home and abroad shows that hyperuric acidemia and gout are systemically affected systemicdiseases, associated with a variety of metabolic diseases, has been highly concerned by the medical community, its diagnosis and treatment also requires multidisciplinary participation80% of human uric acid comes from the body, simple adjustment of living habits to reduce uric acid effect is limited, the treatment of asymptomatic hyperuric acid emisis has clinical significance.